Immunoglobulins subcutaneous immunoglobulin

In a study in which 65 patients switched from intravenous immunoglobulin to subcutaneous immunoglobulins, three patients discontinued subcutaneous administration because of fever, myalgia, and arthralgia in the days after the infusion and switched back to intravenous immunoglobulin [64 ]. 

Susceptibility factors Children Very young children can be treated effectively with subcutaneous immunoglobulins because of poor venous access and often abundant subcutaneous tissues. Three young children tolerated subcutaneous immunoglobulin therapy without incidents [65... 

Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump a retrospective analysis. J Clin Immunol 2010 30(2) 301-7. 

El Shanawany T, Williams P, Pickersgill T, Jolles S. Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin home therapy in a patient with primary immunodeficiency. J Clin Pathol 2010 63(9) 846-7. 

Fieschi C, Bengoufa D, Oksenhendler E. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia decreasing dosage does not alter serum IgG levels. J Clin Immunol 2010 30(4) 602-6. 

Meth MJ, Rosenthal DW, Bonagura VR. Subcutaneous immunoglobulin infusion to treat infants and toddlers with antibody deficiencies. Ann Allergy Asthma Immunol 2010 105(2) 187-8. 

Drug formulations Studies of premedication with hyaluronidase to allow the administration of larger volumes of subcutaneous immunoglobulin at one injection site or the use of a 20% concentration product in order to minimize the volume showed similar rates of adverse reaction as with established subcutaneous immunoglobulin [69 ]. 

Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, Ochs HD. Subcutaneous immunoglobulin opportunities and outlook. Clin Exp Immunol 2009 158(Suppl 1) 51-9. 

Eftimov F, Vermeulen M, de Haan RJ, Van den Berg LH, van Schaik IN. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst 2009 14(2) 93-100. 

Systematic reviews Metanalysis of 1028 individual patients (56.3% with the reported diagnosis of CVID) from 47 articles (10 clinical trials, 17 prospective and 20 retrospective cohorts) found that treatment with home-based subcutaneous immunoglobulin therapy resulted in less headaches, fever and anaphylactoid reactions when compared to hospital-based IVIG therapy (OR 0.09 (0.07-0.11), p< 0.001) [113 ]. 

Machan M, Loren R, Fraga G, Liu D. Pityriasis lichenoides et varioliformis acuta associated with subcutaneous immunoglobulin administration. J Am Acad Dermatol October 2012 67(4) el51-2. 

Bayas A, Gold R, Naumann M. Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions. J Neurol Sci January 15,2013 324(l-2) 53-6. 

Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Qin Immunol July 2004 112(l) l-7. [Research Support, Non-U.S. Gov t Review]. 

Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immtmoglobulin in treatment of primary antibody deficiencies systematic review and meta analysis. J Clin Immunol December 2012 32(6) 1180-92. 

Min J, Bhatt A, Aburashed R, Burton S. Cerebral venous and sinus thrombosis associated with subcutaneous immunoglobulin injection and oral contraceptive use. Neurol Sci official J Italian Neurol Soc Italian Soc CUn Neurophysiol June 2012 33(3) 627-9. 

Shapiro R. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency a retrospective analysis of administration by infusion pump or subcutaneous rapid push. Clin Exp Immunol August 2013 173(2) 365-71. 

Adalimumab (Humira) is a human immunoglobulin Gj monoclonal TNF-a antibody. The binding of adalimumab results in inactivation of the proinflammatory cytokine TNF-a. It is indicated for psoriatic arthritis and treatment of adults with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The recommended dose for psoriatic arthritis is 40 mg subcutaneously every other week. The recommended dose for adults with plaque psoriasis is an initial dose of 80 mg, followed by 40 mg every other week starting 1 week after the initial dose. The most common adverse reactions are infections (e.g., upper respiratory, sinusitis), injection site reactions, headache, and rash. 

Q53 Before initiating treatment with omalizumab, body weight and immunoglobulin E concentration need to be determined. Omalizumab is a monoclonal antibody administered by subcutaneous injection for the prophylaxis of allergic asthma. 

Omalizumab is a monoclonal antibody that binds to immunoglobulin E. It is used as additional therapy in asthma patients who have a proven IgE-mediated sensitivity to inhaled allergens and who are presenting with severe, persistent, uncontrolled asthma. It is administered by subcutaneous injection and the dose is calculated based on the immunoglobulin E concentration and body weight. 

Etanercept is a recombinant fusion protein produced in Chinese hamster ovary cells. It consists of the intracellular ligand-binding portion of the human p75 TNF receptor linked to the Fc portion of human immunoglobulin (Ig) Gi. Two p75 molecules are attached to each Fc molecule. Etanercept binds to soluble TNF-a and TNF-(3 and forms inactive complexes, effectively lowering circulating levels of these cytokines. It is administered subcutaneously, generally twice weekly. 

---